The mechanisms of resistance to TKI include mutations and amplification of Bcr/Abl fusion gene, drug efflux mediated by transporters and bone marrow microenvironment, which lead to aberrant activation of certain signalling pathways in CML cells (Beider et al. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.